Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Net Income (2016 - 2025)

Historic Net Income for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Utah Medical Products' Net Income fell 2615.77% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 2383.01%. This contributed to the annual value of $13.5 million for FY2024, which is 1548.64% down from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' Net Income is $2.6 million, which was down 2615.77% from $3.0 million recorded in Q2 2025.
  • Utah Medical Products' Net Income's 5-year high stood at $4.3 million during Q4 2023, with a 5-year trough of $2.6 million in Q3 2025.
  • Over the past 5 years, Utah Medical Products' median Net Income value was $3.9 million (recorded in 2023), while the average stood at $3.7 million.
  • In the last 5 years, Utah Medical Products' Net Income soared by 16092.92% in 2021 and then tumbled by 3229.12% in 2024.
  • Quarter analysis of 5 years shows Utah Medical Products' Net Income stood at $4.1 million in 2021, then dropped by 0.56% to $4.1 million in 2022, then rose by 4.31% to $4.3 million in 2023, then tumbled by 32.29% to $2.9 million in 2024, then decreased by 9.34% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.